New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
09:24 EDTTSLA, ODP, VVUS, LNKD, BCRX, XOMA, IMUC, M, VSI, SCTY, HD, TMUS, KNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Home Depot (HD), up 1.9%... Vitamin Shoppe (VSI), up 9.6%... ARIAD Pharmaceuticals (ARIA), up 2.4%. ALSO HIGHER: ImmunoCellular (IMUC), up 26% after granted orphan drug designation for ICT-107 by EMA... XOMA (XOMA), up 6% after confirming FDA orphan designation for gevokizumab ... Tesla (TSLA), up 6.5% after price target raised to $320 at Morgan Stanley... BioCryst (BCRX), up 7% after announcing FDA accepted to review peramivir's NDA... LinkedIn (LNKD), up 3.4% after WSJ says the company will expand in China. DOWN AFTER EARNINGS: SolarCity (SCTY), down 2.4%... T-Mobile (TMUS), down 1%... Macy's (M), down 0.5%... Office Depot (ODP), down 13%... ALSO LOWER: VIVUS (VVUS), down 14.5% after earnings, downgrade at JPMorgan.
News For TSLA;TMUS;HD;SCTY;VSI;M;IMUC;XOMA;BCRX;LNKD;VVUS;ODP;KN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 18, 2014
16:22 EDTHDHome Depot completes malware elimination, enhanced encryption of payment data
Subscribe for More Information
16:00 EDTTSLAOptions Update; September 18, 2014
Subscribe for More Information
15:09 EDTVSIVitamin Shoppe holders urge exploration of sale to GNC or pe firm, Reuters says
Subscribe for More Information
14:53 EDTVSIVitamin Shoppe jumps 4% after report of stakeholder urging sale exploration
Subscribe for More Information
14:53 EDTVSIVitamin Shoppe being called on to sell itself by shareholders, Reuters says
Subscribe for More Information
14:09 EDTVVUSVIVUS rallies, mean-reverting to intraday trend line
The shares have traded in an extremely wide range today on nearly 20 times daily average volume. An intraday trend line appears currently to be broken. That line is at $4.60 now, and projecting forward would be at the $4.80 area by the close. At the current price of $4.50, support is at $4.41 and then at $4.32.
12:45 EDTVVUSOn The Fly: Midday Wrap
Subscribe for More Information
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.
10:40 EDTHDPier 1 Imports falls to 12-month low after weak Q2, lowered outlook
Shares of home furnishings retailer Pier 1 Imports (PIR) hit a 12-month low after the company's second quarter results fell below analysts' consensus estimates and it reduced its fiscal 2015 earnings per share outlook. WHAT'S NEW: Pier 1 Imports reported Q2 EPS of 10c on revenue of $418.6M, missing analysts' consensus estimates of 14c and $426.02M, respectively. Same-store-sales for the quarter were up 4.5%. The retailer lowered its FY15 EPS outlook to 95c-$1.05 from $1.14-$1.22. Analysts' consensus estimates for FY15 EPS prior to the earnings report was $1.13. The company sees FY15 SSS in the mid-to-high single digits and gross profit, as a percentage of sales, are expected to be 40.5%-41.5%. Pier 1 Imports CEO Alex Smith said that he foresees online sales to surpass $400M in 2016. WHAT'S NOTABLE: During the company's conference call, Pier 1 Imports said that it expects to see improving merchandise margins in coming quarters with fewer coupons. The company noted plans to continue returning cash to shareholders in the form of dividends and share buybacks. ANALYST REACTION: This morning, Wells Fargo analyst Matt Neemer downgraded Pier 1 Imports to Market Perform from Outperform. He feels that the stock will be a difficult one to own in the medium term as the retailer moves towards a multi-channel approach. Neemer believes that the company has a difficult journey ahead as it cuts broad-based discounters, and he feels that consumers will take time to get accustomed to the new messaging. He cut his price target range to $15-$16 from $19-$20 for the company. Barclays analyst Alan Rifkin downgraded Pier 1 Imports to Equal Weight from Overweight due to slow revenue growth and heightened promotions. He feels that that the "soft" revenues could continue. He believes that the company's elongated online profitability pipeline and increased promotions are certain to be a burden on the business in ways that the company had not initially thought. Rifkin said that growing the top line will be even harder in the absence of promotions. He reduced his price target for shares to $14 from $18. Argus analyst Christopher Graja downgraded Pier 1 Imports to Hold from Buy due to the company's lower than anticipated Q2 earnings. He feels that in terms of the home furnishings market, companies such as Williams-Sonoma (WSM), Home Depot (HD) and Lowe's (LOW) are more "resilient" for shareholders. Pier 1 Imports was also downgraded to Hold from Buy at BB&T. PRICE ACTION: In morning trading, Pier 1 Imports fell $2.63, or 16.99%, to $12.90. Including today's pull back, the stock is down approximately 45.2% over the past 12 months. OTHERS TO WATCH: Other companies in the home furnishings space include Restoration Hardware (RH), and Bed Bath & Beyond (BBBY).
09:36 EDTTSLA, VVUSActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL YHOO TWTR VVUS RAD PWE WFM TSLA PIR SHLD
08:59 EDTVVUSOn The Fly: Pre-market Movers
Subscribe for More Information
08:30 EDTTSLATesla won't be hurt by electric vehicle space struggles, says Pacific Crest
Subscribe for More Information
06:05 EDTVVUSVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.
September 17, 2014
18:05 EDTTSLATesla CEO sees self-driving car technology ready in five or six years, WSJ says
Subscribe for More Information
16:00 EDTTSLAOptions Update; September 17, 2014
iPath S&P 500 VIX Short-Term Futures down 24c to 27.63. Option volume leaders: AAPL TSLA BAC TWTR AMZN X WLT KO PBR according to Track Data.
13:51 EDTHDJPMorgan to replace some credit cards following Home Depot breach, Reuters says
Subscribe for More Information
09:36 EDTTSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL WFM X YHOO TSLA TWTR RAX SHLD SPLS
08:42 EDTTSLASkeptic sees Tesla Model 3 priced well above target, Green Car Reports says
A new report written by noted battery skeptic Menahem Anderman, who organizes the Advanced Automotive Batteries Conference, suggests Tesla Motors' pace of battery cost reduction won't be as fast as predicted by CEO Elon Musk and that the price of the 2017 Model 3 will likely be "in the range of $50-80K, which is well above the company's $35K stated goal, reported Green Car Reports. Reference Link
07:39 EDTLNKDMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
06:05 EDTIMUCImmunoCellular receives positive regulatory feedback on ICT-107
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use